v3.20.1

Contingent assets and liabilities (Details) € in Millions, $ in Millions |  |  |  | 1 Months Ended | 6 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | --- | ---
Jul. 14, 2019 USD ($) | Apr. 01, 2016 | Mar. 13, 2014 EUR (€) | Dec. 31, 2019 USD ($) Milestone | Aug. 31, 2019 USD ($) | Jun. 30, 2017 EUR (€) | Dec. 31, 2019 USD ($) | Dec. 31, 2019 EUR (€) claim | Aug. 23, 2019
Total consideration | € |  |  | € 134.0 |  |  |  |  |  |
Consideration received in cash | € |  |  | 129.0 |  |  |  |  |  |
Potential earn out due upon achievement of a revenue target | € |  |  | € 5.0 |  |  |  |  |  |
Number of months to achieve revenue target |  |  | 12 months |  |  |  |  |  |
Percentage of consideration held in escrow |  |  | 5.00% |  |  |  |  |  |
Number of claims | claim |  |  |  |  |  |  |  | 4 |
Total settlement amount of claims | € |  |  |  |  |  |  |  | € 1.3 |
Amount released from escrow | € |  |  |  |  |  | € 6.6 |  |  |
Period a claim covered by tax deed can be introduced |  | 5 years |  |  |  |  |  |  |
Cost share mechanism |  |  |  |  |  |  |  | 50.00% |
Minimum |  |  |  |  |  |  |  |  |
Cost share mechanism |  |  |  |  |  |  |  |  | 20.00%
Maximum |  |  |  |  |  |  |  |  |
Cost share mechanism |  |  |  |  |  |  |  |  | 50.00%
Gilead | Filgotinib drug license |  |  |  |  |  |  |  |  |
Funding in global development cost (as percentage) |  |  |  |  | 50.00% |  |  |  |
Number of milestones achieved | Milestone |  |  |  | 2 |  |  |  |  |
Potential development and regulatory milestones | $ |  |  |  |  | $ 640 |  |  |  |
Achievement of milestone payments | $ |  |  |  | $ 30 |  |  |  |  |
Gilead | Maximum | Filgotinib drug license |  |  |  |  |  |  |  |  |
Sales based milestone payment | $ |  |  |  |  | $ 600 |  |  |  |
Outside Europe | Minimum |  |  |  |  |  |  |  |  |
Tiered royalty Percentage | 20.00% |  |  |  |  |  |  |  |
Outside Europe | Maximum |  |  |  |  |  |  |  |  |
Tiered royalty Percentage | 24.00% |  |  |  |  |  |  |  |
Filgotinib drug license |  |  |  |  |  |  |  |  |
Proceeds from milestone payments | $ |  |  |  |  |  |  | $ 30 |  |
Sales based milestone payment | $ | $ 600 |  |  |  |  |  |  |  |
Filgotinib drug license | Countries outside of Belgium, France, Germany, Italy, Luxembourg, the Netherlands, Spain and the United Kingdom | Minimum |  |  |  |  |  |  |  |  |
Tiered royalty Percentage | 20.00% |  |  |  | 20.00% |  |  |  |
Filgotinib drug license | Countries outside of Belgium, France, Germany, Italy, Luxembourg, the Netherlands, Spain and the United Kingdom | Maximum |  |  |  |  |  |  |  |  |
Tiered royalty Percentage | 30.00% |  |  |  | 30.00% |  |  |  |
GLPG 1690 License | Outside Europe | Minimum |  |  |  |  |  |  |  |  |
Tiered royalty Percentage | 20.00% |  |  |  |  |  |  |  |
GLPG 1690 License | Outside Europe | Maximum |  |  |  |  |  |  |  |  |
Tiered royalty Percentage | 24.00% |  |  |  |  |  |  |  |

X
- Definition Achievement of milestone payments. + References No definition available. + Details
Name: | glpg_AchievementOfMilestonePayments
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount release from escrow. + References No definition available. + Details
Name: | glpg_AmountReleasedFromEscrow
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition It represents the cost share mechanism for the future development activities, development and sales milestones and royalties. + References No definition available. + Details
Name: | glpg_CostShareForGlobalDevelopmentActivities
Namespace Prefix: | glpg_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The maximum number of years the claim can be submitted. + References No definition available. + Details
Name: | glpg_MaximumNumberOfYearsClaimsCanBeSubmitted
Namespace Prefix: | glpg_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Refers to the number of claims. + References No definition available. + Details
Name: | glpg_NumberOfClaims
Namespace Prefix: | glpg_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents the number of milestones achieved during the period. + References No definition available. + Details
Name: | glpg_NumberOfMilestonesAchieved
Namespace Prefix: | glpg_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Refers to the given amount of months to achieve a desired target. + References No definition available. + Details
Name: | glpg_NumberOfMonthsToAchieveTarget
Namespace Prefix: | glpg_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the percentage of consideration held in escrow. + References No definition available. + Details
Name: | glpg_PercentageOfConsiderationHeldInEscrow
Namespace Prefix: | glpg_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of funding in global development cost. + References No definition available. + Details
Name: | glpg_PercentageOfFundingInGlobalDevelopmentCost
Namespace Prefix: | glpg_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of potential development milestone payments to be received. + References No definition available. + Details
Name: | glpg_PotentialDevelopmentMilestonePayment
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of potential earn out due upon achievement of a revenue target. + References No definition available. + Details
Name: | glpg_PotentialEarnOutDueUponAchievementOfRevenueTarget
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of cash inflow from completion of milestone payments received. + References No definition available. + Details
Name: | glpg_ProceedsFromMilestonePayments
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of sales based milestone payments to be received. + References No definition available. + Details
Name: | glpg_SalesBasedMilestonePaymentsToBeReceived
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of tiered royalties percentage on sales. + References No definition available. + Details
Name: | glpg_TieredRoyaltiesPercentageOnNetSales
Namespace Prefix: | glpg_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The total settlement of claims. + References No definition available. + Details
Name: | glpg_TotalSettlementAmountOfClaims
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Business combinations [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 3 -IssueDate 2019-01-01 -Paragraph B64 -Subparagraph f -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2019-en-r&anchor=para_B64_f&doctype=Appendix&subtype=B -URIDate 2019-03-27 + Details
Name: | ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The portion of consideration paid or received, consisting of cash and cash equivalents, in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Subsidiaries [member]; Cash and cash equivalents; Consideration paid (received)] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 7 -IssueDate 2019-01-01 -Paragraph 40 -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2019-en-r&anchor=para_40_b&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=glpg_GileadSciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_ResearchAndDevelopmentProgramAxis=glpg_FilgotinibDrugLicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=ifrs-full_ForeignCountriesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=glpg_FilgotinibDrugLicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=glpg_CountriesOutsideOfBelgiumFranceGermanyItalyLuxembourgNetherlandsSpainAndUnitedKingdomMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=glpg_Glpg1690LicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |